🇺🇸 FDA
Patent

US 8247564

Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity

granted A61KA61K31/439A61K31/445

Quick answer

US patent 8247564 (Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity) held by Theravance, Inc. expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Aug 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/439, A61K31/445, A61K31/4545, A61P